| Plasma levels of soluble CD14 independently predict mortality in HIV infection NG Sandler, H Wand, A Roque, M Law, MC Nason, DE Nixon, ... Journal of Infectious Diseases 203 (6), 780-790, 2011 | 1353 | 2011 |
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the … F van Leth, P Phanuphak, K Ruxrungtham, E Baraldi, S Miller, B Gazzard, ... The lancet 363 (9417), 1253-1263, 2004 | 900 | 2004 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 594 | 2008 |
| Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis S Teeraananchai, SJ Kerr, J Amin, K Ruxrungtham, MG Law HIV medicine 18 (4), 256-266, 2017 | 592 | 2017 |
| Comprehensive serological profiling of human populations using a synthetic human virome GJ Xu, T Kula, Q Xu, MZ Li, SD Vernon, T Ndung’u, K Ruxrungtham, ... Science 348 (6239), aaa0698, 2015 | 554 | 2015 |
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3 … CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie, MA Johnson, ... The Lancet 378 (9787), 229-237, 2011 | 481 | 2011 |
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised … JV Madruga, D Berger, M McMurchie, F Suter, D Banhegyi, ... The Lancet 370 (9581), 49-58, 2007 | 456 | 2007 |
| Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AM Mills, M Nelson, D Jayaweera, K Ruxrungtham, I Cassetti, PM Girard, ... Aids 23 (13), 1679-1688, 2009 | 357 | 2009 |
| Hiv/aids in asia K Ruxrungtham, T Brown, P Phanuphak The Lancet 364 (9428), 69-82, 2004 | 326 | 2004 |
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ... The Lancet infectious diseases 16 (5), 565-575, 2016 | 321 | 2016 |
| CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial J Ananworanich, A Gayet-Ageron, M Le Braz, W Prasithsirikul, ... The Lancet 368 (9534), 459-465, 2006 | 293 | 2006 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 272 | 2008 |
| Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent J Yuan, S Guo, D Hall, AM Cammett, S Jayadev, M Distel, S Storfer, ... Aids 25 (10), 1271-1280, 2011 | 187 | 2011 |
| Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT … T Puthanakit, J Ananworanich, S Vonthanak, P Kosalaraksa, ... The Pediatric infectious disease journal 32 (5), 501-508, 2013 | 186 | 2013 |
| Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort WP Law, CJ Duncombe, A Mahanontharit, MA Boyd, K Ruxrungtham, ... Aids 18 (8), 1169-1177, 2004 | 186 | 2004 |
| A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand GV Matthews, A Avihingsanon, SR Lewin, J Amin, R Rerknimitr, ... Hepatology 48 (4), 1062-1069, 2008 | 169 | 2008 |
| Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 WP Law, GJ Dore, CJ Duncombe, A Mahanontharit, MA Boyd, ... Aids 17 (15), 2191-2199, 2003 | 168 | 2003 |
| Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients P Cahn, J Fourie, B Grinsztejn, S Hodder, JM Molina, K Ruxrungtham, ... Aids 25 (7), 929-939, 2011 | 153 | 2011 |
| Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults S Walmsley, A Avihingsanon, J Slim, DJ Ward, K Ruxrungtham, J Brunetta, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 50 (4), 367-374, 2009 | 151 | 2009 |
| Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated … C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ... The Lancet HIV 4 (12), e536-e546, 2017 | 150 | 2017 |
Sharon R. LewinDoherty InstituteVerified email at unimelb.edu.au
